UNITED	STATES	BANKR	UPTCY	COURT
SOUTHE	RN DIST	RICT O	F NEW	YORK

In re:

PURDUE PHARMA L.P., et al.,

Debtors.1

Chapter 11

Case No. 19-23649 (RDD)

(Jointly Administered)

ORDER AUTHORIZING THE DEBTORS TO IMPLEMENT 2021 KEY EMPLOYEE INCENTIVE PLAN

Upon the motion (the "Motion")² of Purdue Pharma L.P. and its affiliates that are debtors and debtors in possession in these cases (collectively, the "Debtors") for entry of an order (this "Order") approving and authorizing the 2021 KEIP and the 2021 KERP, as more fully set forth in the Motion; and upon the Lowne Declaration, the Supplemental Lowne Declaration, the Second Supplemental Lowne Declaration, and the Willis Towers Declaration; and the Court having jurisdiction to consider the matters raised in the Motion pursuant to 28 U.S.C. §§ 157 (a)–(b) and 1334(b) and the Amended Standing Order of Reference M-431, dated January 31, 2012 (Preska, C.J.); and consideration of the Motion and the relief requested therein being a core proceeding under 28 U.S.C. § 157(b); and venue being proper before the Court pursuant to 28 U.S.C. §§ 1408 and 1409; and due and proper notice of the Motion having been provided to the

¹ The Debtors in these cases, along with the last four digits of each Debtor's registration number in the applicable jurisdiction, are as follows: Purdue Pharma L.P. (7484), Purdue Pharma Inc. (7486), Purdue Transdermal Technologies L.P. (1868), Purdue Pharma Manufacturing L.P. (3821), Purdue Pharmaceuticals L.P. (0034), Imbrium Therapeutics L.P. (8810), Adlon Therapeutics L.P. (6745), Greenfield BioVentures L.P. (6150), Seven Seas Hill Corp. (4591), Ophir Green Corp. (4594), Purdue Pharma of Puerto Rico (3925), Avrio Health L.P. (4140), Purdue Pharmaceutical Products L.P. (3902), Purdue Neuroscience Company (4712), Nayatt Cove Lifescience Inc. (7805), Button Land L.P. (7502), Rhodes Associates L.P. (N/A), Paul Land Inc. (7425), Quidnick Land L.P. (7584), Rhodes Pharmaceuticals L.P. (6166), Rhodes Technologies (7143), UDF LP (0495), SVC Pharma LP (5717) and SVC Pharma Inc. (4014). The Debtors' corporate headquarters is located at One Stamford Forum, 201 Tresser Boulevard, Stamford, CT 06901.

² Capitalized terms used but otherwise not defined herein will have the meanings set forth in the Motion or the Supplemental Reply Brief (as defined herein), as applicable.

Notice Parties, and it appearing that no other or further notice need be provided; and the Motion's request for relief with respect to the 2021 KERP having been granted as set forth in the Order Authorizing the Debtors to Implement 2021 Key Employee Retention Plan [ECF No. 3571]; and the Debtors having agreed to amend the Motion's request for relief with respect to the 2021 KEIP as set forth in the Debtors' Supplemental Reply Brief (as defined herein); and upon the objections to the Motion's request for approval of the 2021 KEIP, as modified, and the Debtors' reply; and upon the record of the evidentiary hearing held by the Court September 13, 2021 (the "Hearing") and all of the proceedings herein; and after due deliberation and for the reasons stated by the Court in its bench ruling at the Hearing, the Court having determined that the legal and factual bases set forth in the Motion and at the Hearing establish good and sufficient cause for the relief granted herein; and the Court having determined that the relief requested in the Motion with respect to the 2021 KEIP, as modified by the compromise agreed to by the Debtors, the Ad Hoc Committee, the UCC, and the MSGE, and as set forth herein and on the record at the Hearing, is in the best interests of the Debtors, their creditors, their estates, and all other parties in interest; and all objections to the Motion with respect to the 2021 KEIP having been withdrawn, resolved, or overruled,

IT IS HEREBY ORDERED THAT:

- 1. Pursuant to sections 105(a), 363, and 503(c)(3) of the Bankruptcy Code, the Motion is granted as set forth herein.
- 2. The 2021 KEIP is approved in its entirety in the modified form set forth in the Debtors' Supplemental Omnibus Reply in Support of Motion of Debtors for Entry of an Order Authorizing Implementation of 2021 Key Employee Incentive Plan and 2021 Key Employee Retention Plan [ECF No. 3744] (the "Supplemental Reply Brief").

- 3. The Debtors are authorized, but not directed, to take all actions necessary to implement the 2021 KEIP on the terms and conditions set forth in the Motion, but solely as modified by the Supplemental Reply Brief, including making any payments pursuant to the terms of the 2021 KEIP (as modified by the Supplemental Reply Brief).
- 4. Once earned, the Debtors' obligations to pay amounts that become due and owing under the 2021 KEIP shall constitute administrative expenses pursuant to section 503(b) of the Bankruptcy Code, thereby entitled to priority payment pursuant to section 507(a)(2) of the Bankruptcy Code.
- 5. Nothing in this Order or any action taken by the Debtors in furtherance of the implementation hereof shall be deemed to constitute an assumption or rejection of any executory contract or unexpired lease pursuant to section 365 of the Bankruptcy Code, and all of the Debtors' rights with respect to such matters are expressly reserved.
- 6. Notwithstanding the relief granted herein and any actions taken hereunder, nothing contained herein shall (a) create, nor is it intended to create, any rights in favor of, or enhance the status of any claim held by, any person or entity or (b) be deemed to convert the priority of any claim from a prepetition claim into an administrative expense claim.
- 7. Nothing in this Order nor the Debtors' payment of claims pursuant to this Order shall be construed as or deemed to constitute (a) an agreement or admission by the Debtors as to the validity of any claim against the Debtors on any ground, (b) a grant of third-party beneficiary status or bestowal of any additional rights on any third party, (c) a waiver or impairment of any rights, claims, or defenses of the Debtors' rights to dispute any claim on any ground, (d) a promise by the Debtors to pay any claim, or (e) an implication or admission by the Debtors that such claim is payable pursuant to this Order.

19-23649-rdd Doc 3770 Filed 09/15/21 Entered 09/15/21 12:01:51 Main Document Pg 4 of 5

- 8. For the avoidance of doubt, to the extent that any 2021 KEIP Participant is (a) determined by a final order of this Court or any court of competent jurisdiction to have (x) knowingly participated in any criminal misconduct in connection with his or her employment with the Debtors or (y) been aware, other than from public sources, of acts or omissions of others that such participant knew at the time were fraudulent or criminal with respect to the Company's commercial practices in connection with the sale of opioids and failed to report such fraudulent or criminal acts or omissions internally at the Company or to law enforcement authorities at any time during his or her employment with the Company, or (b) believed by the Company based on reasonable inquiry (including inquiry of its attorneys and advisors), which inquiry shall be completed prior to any payments being made to the applicable 2021 KEIP Participant, to have met either of the standards in the foregoing clauses (a)(x) or (y), then in either case such participant shall not be eligible to receive any payments approved by this Order. All parties' rights, if any, to seek disgorgement of payments following the entry of any final order referred to in clause (a) of the foregoing sentence are reserved. The CEO shall not take any action with respect to his compensation under the 2021 KEIP with the intent or material effect of frustrating enforcement of any potential judgment of the Court in these Chapter 11 Cases or any other actions pending against him in any other court or jurisdiction with respect to such amounts.
- 9. Any Bankruptcy Rule (including, but not limited to, Bankruptcy Rule 6004(h)) or Local Rule that might otherwise delay the effectiveness of this Order is hereby waived, and the terms and conditions of this Order shall be effective and enforceable immediately upon its entry.
- 10. The contents of the Motion and the notice procedures set forth therein are good and sufficient notice and satisfy the Bankruptcy Rules and the Local Bankruptcy Rules for the

19-23649-rdd Doc 3770 Filed 09/15/21 Entered 09/15/21 12:01:51 Main Document Pg 5 of 5

Southern District of New York, and no other or further notice of the Motion or the entry of this

Order shall be required.

11. The Debtors are authorized to take all such actions as are necessary or appropriate

to implement the terms of this Order.

12. The Court shall retain exclusive jurisdiction to hear and determine all matters

arising from or related to the implementation, interpretation, and enforcement of this Order.

Dated: September 15, 2021

White Plains, New York

/s/Robert D. Drain

UNITED STATES BANKRUPTCY JUDGE

5